Evidence map›Paper›PMID 41889787›Full record

ArticleFrontiers in genome editing2026

The precision strategy of human genome correction via a set of circular donor DNA and its cleaver.

Kohji Kusano, Kaoru Takizawa, Jitsutaro Kawaguchi, Isamu Hara, Toyotaka Mori

Abstract read
In one paragraph

Article in Frontiers in genome editing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kohji KusanoTsukuba Factory, ID Pharma Co., Ltd., Tsukuba, Ibaraki, Japan.
Kaoru TakizawaTsukuba Factory, ID Pharma Co., Ltd., Tsukuba, Ibaraki, Japan.
Jitsutaro KawaguchiID Pharma Co., Ltd., Chiyoda-ku, Tokyo, Japan.
Isamu HaraTsukuba Factory, ID Pharma Co., Ltd., Tsukuba, Ibaraki, Japan.
Toyotaka MoriID Pharma Co., Ltd., Chiyoda-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Homologous recombination (HR) corrects a mutational sequence causing a genetic disease by replacing it with the normal sequence to restore a healthy state in humans. A targeted genomic breakage, such as that induced by CRISPR-Cas9, can trigger a copy-paste-type HR event; however, CRISPR-Cas9 more frequently induces imprecise non-homologous end-joining events, leading to one-step multiple knockout products for paralogous genes or homologous alleles, which can be considered a unique advantage. We have established a precision strategy for crossover-type HR-based gene editing, primed by intra-cellular circular donor cleavage (InCDC). The InCDC technique generates targeted duplication of the circular donor plasmid at the target locus in human cells, forming a doublet configuration comprising the donor DNA with the designed sequence and the target DNA with the original sequence, with much higher efficiency than conventional donor linearization techniques. This doublet form leads to the singlet form, resulting in retention of the designed allele. We found that the safety distance within the designed circular donor plasmid and its intra-cellular cleavage was particularly critical to protect a designed sequence from enzymatic exclusion, and we propose that InCDC technology enables precision genome editing, such as the replacement of a genetic disease-causing allele with the correctly designed allele.

Indexed as

crossover-type homologous recombinationintra-cellular circular donor cleavagenatural replacementsafety distancetargeted duplication

Identifiers

PMID41889787
PMCPMC13013431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.